“Apparently FDA have a lot of fate in the possibilities of gene-therapy” Interview with Jan Nilsson

“During 2018 CombiGene together with CGT Catapult will drive the process development of our pharmacutical canidate CG01 in order to in 2019 start the regulatory obligatory biodistribution and toxocologystudies. — Jan Nilsson, CEO CombiGene

“This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website”